Next™ BriefMuscle-Preserving Obesity Treatments and Body Composition Therapies
Buy Now
Meticulous Next™HealthcareNov 2026102 ppMRN-1341

Muscle-preserving obesity therapy Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

Brief ID: MRN-1341Format: PDF + Summary DeckDelivery: InstantHorizon: 8-yr horizonSignal: Accelerating
Buy Now · $950
Adoption maturity (indexed)
Mainstream inflection: ~2031
Horizon: 2026–2034 · Signal: Accelerating
8 yrs
Forward horizon
~2031
Mainstream inflection
Accelerating
Signal strength

What This Brief Covers

This Meticulous Next™ brief examines muscle-preserving obesity therapy, drugs that block myostatin and activin signalling to protect lean mass in patients losing weight on GLP-1 and tirzepatide. It tests how fast these drugs move from Phase 2 data to approval in combination with incretins, and which participants capture value among developers, large pharmaceutical firms, manufacturers and payers.

The loss of muscle on incretin drugs is the clinical problem. In the BELIEVE Phase 2b trial of more than 500 patients, Eli Lilly reported weight loss of 22.1% at 72 weeks with bimagrumab plus semaglutide, against 15.7% with semaglutide alone, and 92.8% of the loss came from fat against 71.8% with semaglutide alone. Lean mass fell by about 2.6% to 2.9% with the combination against about 7.4% to 7.9% with semaglutide alone. The conclusion is that blocking the activin pathway roughly halves the lean mass lost per unit of weight, which is the central evidence for the class.

Other antibodies show similar direction. Regeneron reported that trevogrumab with semaglutide preserved 51.3% more muscle in the COURAGE Phase 2 study, rising to 80.9% when garetosmab was added, and Scholar Rock reported that apitegromab with tirzepatide spared about 55% more lean mass than tirzepatide alone in the EMBRAZE Phase 2 study over 24 weeks. The conclusion is that several mechanisms reduce lean mass loss, and the choice between them will turn on tolerability and on whether muscle function improves, which no trial has yet shown.

Tolerability is the main restraint. Analysts reported transient rises in liver enzymes and persistent rises in lipase with bimagrumab, and further reports describe muscle spasms, diarrhoea, acne and higher LDL cholesterol, with one analyst modelling no sales for the drug. The conclusion is that a safer profile, a lower dose or a less frequent schedule is as important as efficacy, and approval is not expected before 2027 at the earliest.

The brief treats muscle-preserving obesity therapy as an accelerating category with an eight year horizon to 2034. It identifies which patients, regions and operators scale first and what each means for developers, large pharmaceutical firms, manufacturers and payers.

It is a focused 102-page decision brief for biopharma firms, payers and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which patients scale first and who captures value.

Brief Snapshot
ParameterDetails
Forward horizon2026–2034 (8 years)
Emerging forceMuscle-preserving obesity therapy: myostatin and activin pathway drugs combined with incretins
Technology readinessPhase 2 data for several antibodies in combination with incretins; no approval in obesity; first approvals not expected before 2027
Indicative market size & forecastUSD 0.02–0.04 billion in 2026, projected to reach USD 2.21–4.41 billion by 2034, at a CAGR of 80%
Mainstream inflection~2031, when approved body composition drugs are used with incretin therapy in patients at risk of muscle loss
Signal strengthPhase 2b data of 22.1% weight loss with 92.8% from fat, and Phase 2 data from two other companies with 51% to 55% less lean mass lost
Primary beneficiariesDevelopers with Phase 2 data and tolerable profiles; large pharmaceutical firms with partnered programmes; CDMOs with antibody capacity
Brief length / format102 pages · PDF + executive summary deck · instant delivery

Understanding the Technology

Myostatin and activin type II receptors restrain muscle growth. Antibodies that block them, such as bimagrumab, trevogrumab, garetosmab and apitegromab, can increase or protect muscle during weight loss.

Bimagrumab binds the activin type II receptors. Lilly acquired it through the purchase of Versanis Bio for nearly USD 2 billion in July 2023.

Other approaches include selective androgen receptor modulators such as enobosarm, and RNA based approaches against activin pathway targets.

Uses are weight management with incretin drugs, with sarcopenia and other muscle indications under study, each under biologic drug regulation.

The limits are an unproven link between lean mass and physical function, tolerability and safety signals, and competition from incretin drugs that are improving on their own. The period turns on whether muscle protection becomes a standard of care.

Market Outlook

The muscle-preserving obesity therapy market, covering sales of approved myostatin, activin and related drugs for body composition in obesity, related licensing and collaboration revenue, and related development and manufacturing services, is valued at USD 0.02–0.04 billion in 2026 and is projected to reach USD 2.21–4.41 billion by 2034, at a CAGR of 80%.

The 2026 base rests on licensing and collaboration income and development services, as no body composition drug is approved for obesity. Growth then follows Phase 3 results, the first approvals and combination use with incretin drugs.

The forecast is sensitive to function and safety data, regulatory endpoints for body composition and payer coverage. Regionally, North America leads on trials and companies, Europe on research and manufacturing, and Asia-Pacific on fast following developers.

Scenarios

The base case assumes Phase 3 trials start in 2027 and report around 2029 and the first approvals follow, giving the inflection in 2031. An accelerated case assumes regulators accept body composition endpoints and an early approval, bringing the inflection to 2029 and lifting the 2034 value to the top of the range. A delayed case assumes safety signals or no functional benefit, holding growth at the bottom of the range.

Factors Behind Growth

Growth drivers

  • Patients losing lean mass on incretin drugs.
  • Phase 2 lean mass results for antibody combinations.
  • Demand from older and frail patients.
  • Extension to sarcopenia and other muscle indications.

Enablers

  • Venture funding and financing rounds.
  • Biopharma licensing and partnerships.
  • Public research funding.
  • Antibody manufacturing capacity.

Restraints and barriers

  • Unproven link between lean mass and function.
  • Competition from tirzepatide and other incretin drugs.
  • Tolerability and safety signals.
  • Cost and complexity of manufacture.

The Forces at Play

The direction of muscle-preserving obesity therapy is set by the need to protect muscle during weight loss, regulation, new targets and formats, biopharma dealmaking and partnering, and manufacturing cost.

Adoption Outlook

How the shift is likely to unfold across three time horizons.

Near term2026–2028
Phase 2 readouts and Phase 3 starts

More Phase 2 data and registrational trial design for combinations.

Mid term2028–2031
First approvals

The first body composition drugs are approved with incretins.

Long term2031–2034
Routine combination use

Muscle protection is routine for patients at risk of lean mass loss.

Latest Strategic Developments

DateDevelopmentTypeSignificance
Jul 2023Eli Lilly acquires Versanis Bio, owner of bimagrumab, for nearly USD 2 billionM&AGives Lilly a lean mass preserving antibody
Jun 2025Eli Lilly presents BELIEVE Phase 2b data at the American Diabetes Association meeting, with 22.1% weight loss and 92.8% of loss from fatClinicalSets the benchmark for the class
Jun 2025Regeneron reports that trevogrumab with semaglutide preserved 51.3% more muscle, and 80.9% with garetosmab added, in the COURAGE Phase 2 studyClinicalAdds a second antibody approach
Jun 2025Scholar Rock reports that apitegromab with tirzepatide spared about 55% more lean mass in the EMBRAZE Phase 2 studyClinicalExtends the evidence to tirzepatide

Key Players & Competitive Landscape

The key participants in muscle-preserving obesity therapy include Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Scholar Rock Holding Corporation, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Biohaven Ltd., Veru Inc., Keros Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., iBio, Inc., 35Pharma Inc., Amgen Inc., Zealand Pharma A/S, Innovent Biologics, Inc., Terns Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., AstraZeneca PLC, AbbVie Inc., Boehringer Ingelheim International GmbH, Sanofi, Bayer AG, Takeda Pharmaceutical Company Limited, Lonza Group Ltd, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Mayo Clinic, Massachusetts General Hospital, American Diabetes Association, The Obesity Society, European Association for the Study of Obesity, Endocrine Society, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, International Council for Harmonisation, Parenteral Drug Association and United States Pharmacopeia.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as muscle-preserving obesity therapy matures.

Eli Lilly leads with bimagrumab and its tirzepatide franchise, Regeneron and Scholar Rock hold the next most advanced antibody programmes, and Roche, Biohaven, Veru, Keros and Arrowhead are earlier, while Novo Nordisk and other incretin owners are the likely partners, and manufacturers, payers, clinical centres, regulators and standards bodies shape adoption. Competitive intensity is low in 2026 because no product is approved, and it rises as Phase 3 programmes start.

ArchetypeRepresentative playersPositionOutlook
Muscle preserving drug developersEli Lilly, Regeneron, Scholar Rock, Biohaven, Veru, Keros Therapeutics, Arrowhead Pharmaceuticals, iBio, 35Pharma, Terns PharmaceuticalsAntibody, SARM and RNA programmesDevelop drugs that protect or build muscle
Large pharmaceutical firmsNovo Nordisk, Roche, Amgen, Novartis, Pfizer, AstraZeneca, AbbVie, Boehringer Ingelheim, Zealand Pharma, Innovent Biologics, Sanofi, Bayer, TakedaObesity and incretin portfoliosLicense, acquire and combine body composition drugs with incretins
Antibody CDMO and tools suppliersLonza, Samsung Biologics, WuXi BiologicsAntibody process development and manufactureMake antibodies at scale
Payers, clinical centres and societiesMayo Clinic, Massachusetts General Hospital, American Diabetes Association, The Obesity Society, European Association for the Study of Obesity, Endocrine SocietyTrials, treatment and clinical guidanceRun trials, deliver treatment and guide use
Government agencies and regulatorsU.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products AdministrationApproval of medicinesApprove trials and products
Standards bodiesInternational Council for Harmonisation, Parenteral Drug Association, United States PharmacopeiaQuality standardsSet quality standards

Where value migrates.

In 2026 value sits with developers of Phase 2 antibody combinations and with the incretin owners that supply the partner drug. By 2031 it moves toward companies with approved body composition drugs and tolerable profiles, because payers and prescribers will pay for products that show function benefit as well as lean mass. By 2034 it settles in integrated incretin and body composition platforms and in CDMOs with antibody capacity at scale. Margins hold for products with a clear tolerability and functional advantage and narrow for late followers on shared targets.

Who Will Win — and Why

The archetypes best positioned to capture value as the shift matures.

Developers with Phase 2 data and tolerable profiles

Firms that show lean mass protection with function benefit and few adverse effects.

Large pharmaceutical firms with partnered programmes

Firms that combine body composition drugs with an incretin franchise.

CDMOs with antibody capacity

Firms that cut cost and time per batch of antibody.

Regulatory Landscape

JurisdictionMilestoneIndicative timingEffect on adoption
FDA guidance for obesity drug developmentUS guidance on endpoints and trial design for weight management drugsIn forceShapes endpoints for body composition claims
EU approval rules for medicinesEU framework for approval of new biologic medicinesIn forceSets the approval path in Europe
Clinical trial approvals in the United States and EuropeRegulatory clearance for first-in-human and early trialsIn forceAllows new programmes to enter patients
Requirements for body composition and function endpointsExpectations that lean mass changes are linked to physical functionIn forceAdd cost and time before approval
Fast track and priority review programmesProgrammes for serious conditions with unmet needIn forceSpeed filings in selected indications

Investment Signals

The signals converge on consistent Phase 2 evidence and an open question on function. Three companies reported lean mass protection of about 50% or more in 2025, with the best result at 22.1% weight loss and 92.8% from fat. Each signal supports growth, and tolerability, function and the lack of any approval limit the pace.

Structural limits show where progress could slow: an unproven link between lean mass and function, tolerability and safety signals, competition from incretin drugs and the cost of manufacture. The brief therefore tracks four indicators: Phase 3 starts, functional endpoint results, safety and discontinuation rates, and partnerships between incretin owners and muscle drug developers.

Combinations in patients at highest risk of muscle loss, then routine use with incretins, then sarcopenia and other muscle indications are the expected order of development.

Questions This Brief Answers

01What is muscle-preserving obesity therapy, and why does it matter?
02What is the market size in 2026, and what is the forecast to 2034?
03What do the BELIEVE, COURAGE and EMBRAZE data indicate?
04What factors are driving growth, and what safety and function barriers remain?
05Which key participants are active, and which archetypes are positioned to win?
06What are the latest developments?
07How will Phase 3 and function data shape adoption between 2026 and 2034?
08What should developers, pharmaceutical firms and payers do now?

Strategic Implications

  • Muscle preserving drug developers: show function benefit with a clean safety profile and secure incretin partners.
  • Large pharmaceutical firms: decide whether to build, license or buy body composition assets to pair with incretin drugs.
  • Payers, clinical centres and research groups: define the patients and endpoints for which muscle protection is worth paying for.
  • Policy makers: clarify evidence expectations for body composition and function endpoints.
  • Investors: treat Phase 3 starts, function data, safety data and partnerships as the leading indicators.
Analyst Perspective

"Weight loss that is nine tenths fat is a better result than weight loss that is seven tenths fat. Whether it also means stronger patients is what Phase 3 has to show."

Lead Foresight Analyst
Biotechnology & Life Sciences · Meticulous Next™

Table of Contents

Access & Licensing

A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.

Single Brief
$950
One named user
Full PDF brief
Executive summary deck
One named user
Free outlook update
★ Most Popular
Team License
$1,350
Up to 10 users
Access for 2–10 users
Internal sharing rights
30-minute analyst briefing
Enterprise
$2,150
Organization-wide
Organization-wide access
Unlimited users
Priority analyst access
Custom extracts
Included with
every brief
Analyst-reviewed foresightMulti-signal validationInstant deliveryFree outlook updates

Frequently Asked Questions

Search Market Intelligence

Search across reports, blogs, press releases, and industries